John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Harold S, Dienes K. The influence of ethnicity and nationality on cortisol reactivity to an acute laboratory stressor, with and without partner support. Poster presented at the American Psychosomatic Society 77th Annual Scientific Meeting; March 2019. Vancouver, Canada. [abstract] Psychosom Med. 2019 May; 81(4):A71. doi: 10.1097/PSY.0000000000000699
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Wesselink AK, Wise LA, Rothman KJ, Hahn KA, Mikkelsen EM, Mahalingaiah S, Hatch EE. Caffeine and caffeinated beverage consumption and fecundability in a preconception cohort. Reprod Toxicol. 2016 Jul;62:39-45. doi: 10.1016/j.reprotox.2016.04.022
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Evans MF, Poulos C, Smith VK. Who counts in evaluating the effects of air pollution policies on households? Non-market valuation in the presence of dependencies. J Environ Econ Manage. 2011 Jul 1;62(1):65-79.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Smith VK, Mansfield CA. Buying time: real and hypothetical offers. J Environ Econ Manage. 1998;36(3):209-24.